Our findings indicated that, in pathology-confirmed prostate cancer with neuroendocrine differentiation, AR still expressed and functioned in a considerable part of the tumor; loss of AR expression was associated with adverse clinical stage and poor cancer cell differentiation. Here, AR is linked to cancer.